Katie joined The Lily Foundation in January this year in the role of Science & Patient Engagement Officer, strengthening our mission to promote patient advocacy and a patient-centred approach to mitochondrial research.
Her election to the board of IMP complements that role, and continues The Lily Foundation's involvement at the heart of global mitochondrial disease research. Katie will take over the position on the IMP board from Alison Maguire, The Lily Foundation's Head of Research, who is stepping down to focus on Lily research collaborations.
IMP is a network of 16 international mito patient organisations, with members in the UK, Canada, Spain, France, Italy, The Netherlands, USA, Belgium, Bulgaria, Finland and Australia. The network aims to support and advocate for patients, fund research, raise awareness and improve worldwide education about mitochondrial disease. By joining forces, IMP aims to create a stronger, consistent message on an international level.
Commenting on her IMP role, Katie said: "I'm very proud to be representing The Lily Foundation on the IMP board, and look forward to continuing the excellent work that Alison has started. In my role at The Lily Foundation I'm privileged to be in regular contact with many UK families affected by a mitochondrial disease diagnosis, and this will inform my participation as a member of the IMP board. I look forward to collaborating with the other IMP members, learning from one another's experiences and achievements, as we work towards our shared goal to improve the lives of people affected by mitochondrial disorders."
Before joining The Lily Foundation, Katie spent over five years working as a research nurse, caring for children with rare neuromuscular conditions. Since joining the charity she has been involved in the IMP-coordinated GENOMIT project, as well as other international mitochondrial disease initiatives such as the Leigh Syndrome Roadmap Project.